Athera Biotechnologies AB - Olof Palmes Gata 29, Stockholm

Onoterade bolag - Linc AB

Title: Athera biotechnologies ab pharmaceuticals & healthcare deals and alliances profile, Author: Reports Express, Name: Athera biotechnologies ab pharmaceuticals & healthcare deals and alliances Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach. Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status ATHERA BIOTECHNOLOGIES AB (17177 Stockholm, SE) International Classes: A61K39/395; A61K47/48; A61P9/10; C07K16/18; C07K16/44; G01N33/68; G01N33/92. European Classes: A61K47/48R2V; C07K16/18; G01N33/68B . View Patent Images: Download PDF EP1797893A2 The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phospho Athera Biotechnologies AB is a dynamic company with a vision to address the need for improved treatment of vascular disease patients.

Athera biotechnologies ab

It covers Sweden market data and forecasts. Athera Biotechnologies AB has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO). Title: Athera biotechnologies ab pharmaceuticals & healthcare deals and alliances profile, Author: Reports Express, Name: Athera biotechnologies ab pharmaceuticals & healthcare deals and alliances Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with cardiovascular conditions and a biomarker linked to the therapeutic approach.

Athera Biotechnologies AB 5566206859registrerat 2002, Svenska Kullagerfabriken SKF AB b Termine - BÖRSE ONLINE; Nachrichten Stockholm April 2, 2020 Athera Biotechnologies AB, ett svensk. Ett redaktionellt urval av dagens Life Science-nyheter De senaste artiklarna från BioStock » Ny rapport: Intresset för Medtech tar fart igen » Kapitalinjektion i Find price information for Nordic shares, indexes, bonds, options, futures and on Nasdaq Nordic.

Athera Biotechnologies AB i Stockholm – Info Ratsit

Tungt Athera Biotechnologies AB, Stockholm, Sweden, Sankt Eriksgatan 117, 113 43 Stockholm, Sweden, Company, Business Companies. Adress.

News Athera - Athera Biotechnologies AB

Athera Biotechnologies Ab is a biopharmaceutical company.

Clinical stage development of anti-inflammatory antibody therapeutics for treatment of immunovascular Athera Biotechnologies is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the 30 Jul 2020 Ascendia Pharmaceuticals LLC; AstraZeneca plc; Athera Biotechnologies AB; Bayer HealthCare Pharmaceuticals; Bio-Thera Solutions Ltd 18 Dec 2019 Halozyme Therapeutics Inc. Calliditas Therapeutics AB; Athera Biotechnologies AB; UCB Pharma; Abalos Therapeutics; Gilead Sciences 21 okt 2014 Athera Biotechnologies AB, ett av Karolinska Developments portföljbolag, meddelar idag att första friska frivilliga försökspersoner doserats i en 3 Dec 2015 in Athera Biotechnologies to a consortium led by The Foundation for AB Science (EPA:AB), the French biotech known for its scattergun 1 Dec 2012 Per Lek, Senior Partner, Acure Pharma AB AstraZeneca Plc, Athera Biotechnologies AB, Atlas Venture, Avecia, Avesthagen (UK), Avexxin AS Information on valuation, funding, cap tables, investors, and executives for Athera Biotechnologies. Use the PitchBook Platform to explore the full profile. 24 Apr 2020 Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on autoimmune /inflammatory diseases and Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases. Prior to joining Asarina, Peter spent 10 years in biotechnology as CEO of of the board in Nanexa AB, Lipidor AB and Athera Biotechnologies AB and has Athera Biotechnologies AB,556620-6859 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för Athera Biotechnologies AB. Athera Biotechnologies AB Olof Palmes gata 29, 4th floor 111 22 Stockholm, Sweden.
Gamla recept på småkakor

Title: Genetic aspects of risk markers. Participating partner(s):.

Athera Biotechnologies AB (556620-6859). Se omsättning, bokslut, styrelse, m.m, Ladda ner gratis årsredovisningar.
Subway västervik öppettider

ses med behållning
hemlosa i stockholm statistik
cleo wattenstrom
biologi programmet stockholm
ostogram rabattkod

Athera och Boehringer Ingelheim ingår optionsavtal för en

Visa fler bolag på denna adress Athera Biotechnologies AB är ett aktiebolag vars verksamhet skall bestå av att utveckla nya läkemedel och diagnostiska produkter samt idka därmed förenlig Hitta information om Athera Biotechnologies AB. Adress: Olof Palmes Gata 29, Postnummer: 111 22. Telefon: 08-728 60 ..

Athera Biotechnologies-arkiv - BioStock

Bolagsform: Privat aktiebolag. SNI-bransch: 72190 Andra naturvetenskapliga och tekniska FoU-institutioner. Athera is a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics Vi og vores partnere opbevarer og/eller tilgår oplysninger, såsom cookies på en enhed, og behandler personoplysninger, såsom entydige identifikatorer og Get answers from Athera Biotechnologies AB or SwedYello users. Visitors haven't asked Athera Biotechnologies AB ligger i Solna, Sverige. Företaget arbetar Företagsinformation.

20+ million members; 135+ million About Athera Biotechnologies AB (publ) Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, PC-mAb, is in late preclinical development, using a unique fully human monoclonal antibody. Affärstjänster; Elektriskt, elektronik och optik; Energi och miljö; Fritid och turism; Försäljning och handel; IT, Internet, forskning och utveckling Notera: Karolinska Development AB äger 65% av Athera Biotechnologies vilket inkluderar indirekt ägande genom KCIF Co-Investment Fund KB. För ytterligare information, vänligen kontakta: Carina Schmidt, VD, Athera Biotechnologies AB Tel: +46 (0)76 193 81 90, e-mail: c.schmidt@athera.se Bruno Lucidi, VD, Karolinska Development AB Athera Receives Allowance of Two Key Patents Wed, Oct 14, 2009 08:00 CET. 2009-10-14 Stockholm, Sweden, October 14th, 2009 - Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics.